Search
for

    Glossary KX826

    KX826 is a novel topical treatment developed for androgenetic alopecia, commonly known as male or female pattern hair loss. It functions as a dual-action agent, targeting both the androgen receptors and promoting hair follicle growth, which distinguishes it from traditional treatments like minoxidil and finasteride. Its relevance lies in its potential to offer a more effective solution for hair regrowth by addressing the hormonal factors contributing to hair loss while also stimulating hair follicle activity. Clinical trials have shown promising results, making KX826 a noteworthy option in the evolving landscape of hair loss therapies.

    Related Terms

    Learn

    2 / 2 results

      learn KX-826

      • Kintor Pharmaceutical: KX-826, a New Name in Hair Loss Research KX-826 (pyrilutamide) is an experimental topical androgen receptor blocker from Kintor Pharmaceutical and is not approved as a medicine anywhere. Its first China Phase III trial did not beat placebo; the company reported in March 2026 that a later Phase III of a 1.0% formulation met its primary endpoint, but these results are company announcements, not peer-reviewed, and long-term safety is unknown.

      learn Pyrilutamide

      Experimental topical anti-androgen, also known as KX-826

    Community Join

    5 / 351 results

      community KX826 New Phase 3 Trial In China for 2025: 1.0% concentration

       62 upvotes 1 year ago
      KX-826 is undergoing Phase III trials in China as a potential treatment for male pattern baldness, with some users considering it as an alternative or addition to finasteride and dutasteride. Opinions on its effectiveness vary, with some users reporting positive results and others finding it expensive and ineffective.

      community GT20029 & KX826 Major Updates from Kintor.

       101 upvotes 1 year ago
      KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

    Research

    2 / 13 results